Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of KH607 Tablets in the Treatment of Major Depressive Disorder
NCT07741240 is registered in ClinicalTrials.gov with Chengdu Kanghong Pharmaceutical Group Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of KH607 Tablets in the Treatment of Major Depressive Disorder
- Lead sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- July 31, 2026
- Completion date
- December 31, 2027
- Enrollment
- 232 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
major depressive disorder (mdd)